Publications
Where expertise meets impact
Berry doesn’t just follow industry standards — we set them. Our team of award-winning statisticians, journal editors, and regulatory advisors leads the field in Bayesian and adaptive trial design. With research published in The New England Journal of Medicine, JAMA, and The Lancet, we’re driving innovation where it matters most.
Over 90% of our scientists published influential work this past year, advancing adaptive, Bayesian, and platform trial methodology. Our blend of academic rigor, regulatory insight, and real-world experience makes Berry a true authority in modern clinical trials.
Explore our most impactful peer-reviewed publications below.

Springer Nature
Infectious Disease
Platform
Statistical documentation for multi-disease, multi-domain platform trials: our experience with the Staphylococcus aureus Network Adaptive Platform trial
February 11, 2025
2025
DOI: 10.1186/s13063-024-08684-8
Springer Nature
Methodology
Platform
Why and how should we simulate platform trials? Learnings from EU-PEARL
January 17, 2025
2025
DOI: 10.1186/s12874-024-02453-6
Annals of Internal Medicine
Infectious Disease
Meta-analysis
Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis
January 17, 2025
2025
DOI: 10.7326/ANNALS-24-00800
Stroke
Neuroscience
Stroke
Platform
Adaptive Platform Trials in Stroke
December 20, 2024
2024
doi.org/10.1161/STROKEAHA.124.045754
JAMA Network Open
Platform
The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design
December 11, 2024
2024
doi:10.1001/jamanetworkopen.2024.49998
Trials Journal
Infectious Disease
Platform
A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial
December 6, 2024
2024
doi: 10.1186/s13063-023-07718-x.
JAMA Network Open
Mechanical Ventilation
Factorial Design
Ventilator Weaning Strategies-Managing Interaction Between Randomized Treatments
December 3, 2024
2024
DOI: 10.1001/jama.2024.19853
JCO Oncology Advances
Oncology
Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial
November 27, 2024
2024
doi.org/10.1200/OA-24-00044
No results found.
There are no results with this criteria. Try changing your search.